What is Usana Health Sciences Inc's earnings per share (EPS)?

Usana Health Sciences Inc (USNA) reported diluted earnings per share of $0.58 for fiscal year 2026. This represents a -73.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Usana Health Sciences Inc Financials

USNA

Source SEC Filings (10-K/10-Q) Updated Apr 4, 2026 Currency USD FYE January

This page shows Usana Health Sciences Inc (USNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI USNA FY2026 2026-04-22

Sales recovery was absorbed by a heavier overhead base and weaker cash conversion instead of translating into stronger earnings.

The most revealing shift is cash conversion: even as sales recovered, operating cash flow fell to $22.3M from $61.0M, so the rebound showed up in revenue faster than it showed up in cash. With inventory rising to $102.6M and SG&A reaching $337.4M, the company appears to be carrying more stock and more selling/administrative cost for each dollar of business than it did a year earlier.

The balance sheet still looks cushioned: current liquidity remains 2.2x, and liabilities sit at only 0.3x equity. That leaves room to absorb a softer earnings period without stretching the balance sheet, even with free cash flow down to $8.5M.

Margin compression is happening above and below the operating line: gross margin slipped to 78.3% while operating margin fell to 4.1%. Because gross margin remains high but operating profitability deteriorated much more, the latest pressure looks more tied to selling and administrative burden than to core product cost alone.

Financial Health Signals

Financial Profile 45/100

Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Usana Health Sciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Usana Health Sciences Inc has an operating margin of 4.0%, meaning the company retains $4 of operating profit per $100 of revenue. This results in a moderate score of 36/100, indicating healthy but not exceptional operating efficiency. This is down from 7.8% the prior year.

Growth

Usana Health Sciences Inc's revenue grew 8.3% year-over-year to $925.3M, a solid pace of expansion. This earns a growth score of 34/100.

Leverage

Usana Health Sciences Inc carries a low D/E ratio of 0.27, meaning only $0.27 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Usana Health Sciences Inc's current ratio of 2.51 indicates adequate short-term liquidity, earning a score of 47/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Usana Health Sciences Inc has a free cash flow margin of 0.9%, earning a moderate score of 34/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Usana Health Sciences Inc generates a 2.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 24/100. This is down from 7.9% the prior year.

Altman Z-Score Safe

4.06

Usana Health Sciences Inc scores 4.06, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

6/9

Usana Health Sciences Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.08x

For every $1 of reported earnings, Usana Health Sciences Inc generates $2.08 in operating cash flow ($22.3M OCF vs $10.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

44.5x

Usana Health Sciences Inc earns $44.5 in operating income for every $1 of interest expense ($37.4M vs $842K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$925.3M

YoY+8.3%

5Y CAGR-2.7%

10Y CAGR+2.6%

Usana Health Sciences Inc generated $925.3M in revenue in fiscal year 2026. This represents an increase of 8.3% from the prior year.

EBITDA

$70.0M

YoY-13.4%

5Y CAGR-15.3%

10Y CAGR-5.7%

Usana Health Sciences Inc's EBITDA was $70.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.4% from the prior year.

Net Income

$10.8M

YoY-74.4%

5Y CAGR-36.0%

10Y CAGR-18.1%

Usana Health Sciences Inc reported $10.8M in net income in fiscal year 2026. This represents a decrease of 74.4% from the prior year.

EPS (Diluted)

$0.58

YoY-73.5%

5Y CAGR-33.4%

10Y CAGR-20.2%

Usana Health Sciences Inc earned $0.58 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 73.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$8.5M

YoY-83.3%

5Y CAGR-40.1%

10Y CAGR-21.1%

Usana Health Sciences Inc generated $8.5M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 83.3% from the prior year.

Cash & Debt

$162.8M

YoY-10.5%

5Y CAGR-7.1%

10Y CAGR+1.7%

Usana Health Sciences Inc held $162.8M in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY-3.2%

5Y CAGR-3.1%

10Y CAGR+2.9%

Usana Health Sciences Inc had 18M shares outstanding in fiscal year 2026. This represents a decrease of 3.2% from the prior year.

Margins & Returns

Gross Margin

78.3%

YoY-2.8pp

5Y CAGR-4.0pp

10Y CAGR-4.0pp

Usana Health Sciences Inc's gross margin was 78.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 2.8 percentage points from the prior year.

Operating Margin

4.0%

YoY-3.7pp

5Y CAGR-9.7pp

10Y CAGR-12.2pp

Usana Health Sciences Inc's operating margin was 4.0% in fiscal year 2026, reflecting core business profitability. This is down 3.7 percentage points from the prior year.

Net Margin

1.2%

YoY-3.8pp

5Y CAGR-8.3pp

10Y CAGR-9.8pp

Usana Health Sciences Inc's net profit margin was 1.2% in fiscal year 2026, showing the share of revenue converted to profit. This is down 3.8 percentage points from the prior year.

Return on Equity

2.0%

YoY-5.9pp

5Y CAGR-26.6pp

10Y CAGR-28.4pp

Usana Health Sciences Inc's ROE was 2.0% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.7M

YoY-7.6%

5Y CAGR+0.8%

10Y CAGR+7.7%

Usana Health Sciences Inc invested $10.7M in research and development in fiscal year 2026. This represents a decrease of 7.6% from the prior year.

Share Buybacks

$27.5M

YoY+191.3%

5Y CAGR-28.8%

10Y CAGR+4.3%

Usana Health Sciences Inc spent $27.5M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 191.3% from the prior year.

Capital Expenditures

$13.8M

YoY+37.2%

5Y CAGR-3.6%

10Y CAGR+5.6%

Usana Health Sciences Inc invested $13.8M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 37.2% from the prior year.

USNA Income Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Revenue	$925.3M+8.3%	$854.5M-7.2%	$921.0M-7.8%	$998.6M-12.0%	$1.1B+7.0%	$1.1B
Cost of Revenue	$200.9M+24.6%	$161.2M-8.8%	$176.7M-8.9%	$193.9M-7.3%	$209.1M+11.5%	$187.5M
Gross Profit	$724.4M+4.5%	$693.3M-6.9%	$744.3M-7.5%	$804.7M-13.1%	$925.5M+6.0%	$873.4M
R&D Expenses	$10.7M-7.6%	$11.6M+1.1%	$11.4M-1.0%	$11.6M+8.7%	$10.6M+3.6%	$10.3M
SG&A Expenses	$337.4M+28.1%	$263.3M+2.4%	$257.0M-2.0%	$262.3M+0.4%	$261.2M-2.4%	$267.7M
Operating Income	$37.4M-43.6%	$66.3M-28.7%	$93.1M-13.5%	$107.6M-39.0%	$176.5M+20.7%	$146.2M
Interest Expense	$842K+199.6%	$281K+7.3%	$262K+36.5%	$192K-62.1%	$507K+668.2%	$66K
Income Tax	$30.1M-12.4%	$34.3M-11.3%	$38.7M-1.5%	$39.3M-26.3%	$53.3M+6.6%	$50.0M
Net Income	$10.8M-74.4%	$42.0M-34.1%	$63.8M-8.0%	$69.3M-44.4%	$124.7M+24.0%	$100.5M
EPS (Diluted)	$0.58-73.5%	$2.19-33.6%	$3.30-8.1%	$3.59-38.7%	$5.86+32.9%	$4.41

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Revenue	$250.2M+10.6%	$226.2M+5.9%	$213.7M-9.4%	$235.8M-5.5%	$249.5M+16.8%	$213.6M+6.7%	$200.2M-5.9%	$212.9M
Cost of Revenue	$59.4M+20.3%	$49.4M+1.2%	$48.8M-2.7%	$50.2M-4.3%	$52.4M+36.0%	$38.6M-1.8%	$39.3M-2.7%	$40.3M
Gross Profit	$190.8M+7.9%	$176.8M+7.2%	$164.9M-11.2%	$185.7M-5.8%	$197.1M+12.6%	$175.1M+8.8%	$161.0M-6.7%	$172.5M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$88.3M+13.0%	$78.1M-9.2%	$85.9M+4.9%	$81.9M-10.4%	$91.4M+24.7%	$73.3M+19.7%	$61.3M-4.7%	$64.3M
Operating Income	$13.9M+263.3%	$3.8M+212.0%	$1.2M-92.7%	$16.7M+6.7%	$15.7M+90.9%	$8.2M-47.4%	$15.6M-12.6%	$17.8M
Interest Expense	$240K+95.1%	$123K+151.0%	$49K-81.1%	$259K-37.0%	$411K+218.6%	$129K+163.3%	$49K-3.9%	$51K
Income Tax	$8.5M+47.4%	$5.8M-31.7%	$8.5M+1.0%	$8.4M+12.4%	$7.4M+25.3%	$5.9M-25.7%	$8.0M-18.1%	$9.8M
Net Income	$7.5M+523.4%	-$1.8M+72.8%	-$6.5M-167.6%	$9.7M+2.7%	$9.4M+111.1%	$4.5M-58.0%	$10.6M+1.7%	$10.4M
EPS (Diluted)	$0.41	N/A	$-0.36-169.2%	$0.52+6.1%	$0.49	N/A	$0.56+3.7%	$0.54

USNA Balance Sheet

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Total Assets	$739.0M-1.2%	$748.2M+18.2%	$632.8M+6.1%	$596.5M+2.1%	$584.5M+13.1%	$516.9M
Current Assets	$294.2M+5.4%	$279.2M-33.2%	$417.7M+8.7%	$384.4M+3.0%	$373.2M+13.3%	$329.3M
Cash & Equivalents	$162.8M-10.5%	$181.8M-45.0%	$330.4M+14.6%	$288.4M+12.2%	$257.0M+9.4%	$234.8M
Inventory	$96.4M+38.2%	$69.7M+13.5%	$61.5M-8.4%	$67.1M-23.5%	$87.6M+27.2%	$68.9M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$138.1M-4.2%	$144.2M+743.0%	$17.1M-1.5%	$17.4M+0.3%	$17.3M+4.1%	$16.6M
Total Liabilities	$144.2M-10.9%	$161.9M+19.4%	$135.6M-16.4%	$162.1M-10.8%	$181.7M+10.0%	$165.2M
Current Liabilities	$117.2M-16.0%	$139.6M+17.5%	$118.8M-17.4%	$143.8M-5.0%	$151.5M+11.3%	$136.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$543.5M+2.2%	$532.1M+7.0%	$497.2M+14.4%	$434.5M+7.9%	$402.8M+14.5%	$351.7M
Retained Earnings	$473.2M-1.2%	$478.9M+7.6%	$445.2M+13.7%	$391.6M+10.9%	$353.2M+15.4%	$306.1M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Total Assets	$739.0M-0.5%	$742.9M+2.2%	$726.6M-1.1%	$734.5M-1.6%	$746.6M-0.2%	$748.2M+11.5%	$671.3M+6.3%	$631.4M
Current Assets	$294.2M+2.0%	$288.4M+9.2%	$264.1M+0.8%	$261.9M-6.9%	$281.4M+0.8%	$279.2M-38.1%	$451.2M+7.7%	$419.1M
Cash & Equivalents	$162.8M+2.8%	$158.4M+9.0%	$145.3M-4.0%	$151.3M-15.7%	$179.6M-1.2%	$181.8M-50.2%	$364.9M+9.8%	$332.4M
Inventory	$96.4M-6.1%	$102.6M+13.0%	$90.8M+9.0%	$83.3M+13.2%	$73.6M+5.5%	$69.7M+9.0%	$64.0M+3.5%	$61.8M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$138.1M+0.1%	$138.0M-4.4%	$144.3M0.0%	$144.2M0.0%	$144.2M0.0%	$144.2M+738.4%	$17.2M+2.1%	$16.8M
Total Liabilities	$144.2M-8.0%	$156.6M+8.0%	$145.0M-2.6%	$149.0M-8.5%	$162.7M+0.5%	$161.9M+17.1%	$138.2M+15.9%	$119.2M
Current Liabilities	$117.2M-8.8%	$128.6M+8.3%	$118.7M-2.4%	$121.6M-11.5%	$137.4M-1.6%	$139.6M+21.6%	$114.8M+10.5%	$103.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$543.5M+2.0%	$533.1M+1.0%	$528.1M-0.6%	$531.1M+0.2%	$529.8M-0.4%	$532.1M-0.2%	$533.1M+4.1%	$512.2M
Retained Earnings	$473.2M+1.6%	$465.7M-0.4%	$467.5M-1.4%	$474.0M-0.8%	$477.6M-0.3%	$478.9M+0.9%	$474.5M+2.3%	$463.9M

USNA Cash Flow Statement

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Operating Cash Flow	$22.3M-63.4%	$61.0M-13.7%	$70.6M-32.0%	$103.9M-35.2%	$160.4M+26.6%	$126.7M
Capital Expenditures	$13.8M+37.2%	$10.1M-30.5%	$14.5M+39.4%	$10.4M-31.1%	$15.1M-8.9%	$16.6M
Free Cash Flow	$8.5M-83.3%	$50.9M-9.3%	$56.1M-40.0%	$93.5M-35.7%	$145.3M+31.9%	$110.2M
Investing Cash Flow	-$10.1M+95.2%	-$213.1M-1679.5%	-$12.0M+3.2%	-$12.4M+63.6%	-$34.0M-171.5%	$47.5M
Financing Cash Flow	-$40.6M-525.0%	$9.6M+167.1%	-$14.2M+52.7%	-$30.1M+49.4%	-$59.4M+60.9%	-$152.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$27.5M+191.3%	$9.4M-18.6%	$11.6M-54.3%	$25.4M-55.5%	$57.0M-62.0%	$150.0M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Operating Cash Flow	$9.8M+387.9%	-$3.4M-72.9%	-$2.0M-116.1%	$12.2M-21.1%	$15.5M+167.6%	$5.8M-80.4%	$29.5M+269.6%	$8.0M
Capital Expenditures	$2.6M-5.4%	$2.8M-12.6%	$3.2M-36.4%	$5.0M+79.3%	$2.8M+55.5%	$1.8M-24.9%	$2.4M-10.2%	$2.7M
Free Cash Flow	$7.1M+215.0%	-$6.2M-19.9%	-$5.2M-171.7%	$7.2M-43.3%	$12.7M+218.3%	$4.0M-85.3%	$27.1M+410.2%	$5.3M
Investing Cash Flow	-$2.6M-334.0%	$1.1M+134.7%	-$3.2M+23.2%	-$4.2M-7.4%	-$3.9M+98.1%	-$205.1M-8674.1%	-$2.3M-51.2%	-$1.5M
Financing Cash Flow	-$3.6M-127.1%	$13.5M+1474.2%	-$979K+97.5%	-$38.6M-166.9%	-$14.5M-163.1%	$22.9M+29497.4%	-$78K+94.2%	-$1.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0	$0-100.0%	$15.2M+23.6%	$12.3M	$0	$0	$0

USNA Financial Ratios

Metric	FY26	FY24	FY23	FY22	FY21	FY19
Gross Margin	78.3%-2.8pp	81.1%+0.3pp	80.8%+0.2pp	80.6%-1.0pp	81.6%-0.8pp	82.3%
Operating Margin	4.0%-3.7pp	7.8%-2.3pp	10.1%-0.7pp	10.8%-4.8pp	15.6%+1.8pp	13.8%
Net Margin	1.2%-3.8pp	4.9%-2.0pp	6.9%-0.0pp	6.9%-4.0pp	11.0%+1.5pp	9.5%
Return on Equity	2.0%-5.9pp	7.9%-4.9pp	12.8%-3.1pp	16.0%-15.0pp	30.9%+2.4pp	28.6%
Return on Assets	1.5%-4.2pp	5.6%-4.5pp	10.1%-1.6pp	11.6%-9.7pp	21.3%+1.9pp	19.4%
Current Ratio	2.51+0.5	2.00-1.5	3.52+0.8	2.67+0.2	2.46+0.0	2.42
Debt-to-Equity	0.27-0.0	0.30+0.0	0.27-0.1	0.37-0.1	0.45-0.0	0.47
FCF Margin	0.9%-5.0pp	6.0%-0.1pp	6.1%-3.3pp	9.4%-3.4pp	12.8%+2.4pp	10.4%

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Gross Margin	76.3%-1.9pp	78.2%+1.0pp	77.1%-1.6pp	78.7%-0.3pp	79.0%-3.0pp	82.0%+1.6pp	80.4%-0.7pp	81.0%
Operating Margin	5.5%+3.9pp	1.7%+1.1pp	0.6%-6.5pp	7.1%+0.8pp	6.3%+2.4pp	3.8%-4.0pp	7.8%-0.6pp	8.4%
Net Margin	3.0%+3.8pp	-0.8%+2.3pp	-3.0%-7.1pp	4.1%+0.3pp	3.8%+1.7pp	2.1%-3.2pp	5.3%+0.4pp	4.9%
Return on Equity	1.4%+1.7pp	-0.3%+0.9pp	-1.2%-3.1pp	1.8%+0.1pp	1.8%+0.9pp	0.8%-1.2pp	2.0%-0.1pp	2.0%
Return on Assets	1.0%+1.3pp	-0.2%+0.7pp	-0.9%-2.2pp	1.3%+0.1pp	1.3%+0.7pp	0.6%-1.0pp	1.6%-0.1pp	1.7%
Current Ratio	2.51+0.3	2.24+0.0	2.23+0.1	2.15+0.1	2.05+0.0	2.00-1.9	3.93-0.1	4.03
Debt-to-Equity	0.27-0.0	0.29+0.0	0.270.0	0.28-0.0	0.310.0	0.30+0.0	0.26+0.0	0.23
FCF Margin	2.8%+5.6pp	-2.7%-0.3pp	-2.4%-5.5pp	3.0%-2.0pp	5.1%+3.2pp	1.9%-11.7pp	13.6%+11.1pp	2.5%

Similar Companies

Oatly Group Ab OTLY

$257.0M

WESTROCK COFFEE CO WEST

$735.6M

Lifeway Food LWAY

$359.1M

Seneca Foods Corp SENEB

$987.2M

John B. Sanfilippo & Son JBSS

$882.0M

Frequently Asked Questions

What is Usana Health Sciences Inc's annual revenue?

Usana Health Sciences Inc (USNA) reported $925.3M in total revenue for fiscal year 2026. This represents a 8.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Usana Health Sciences Inc's revenue growing?

Usana Health Sciences Inc (USNA) revenue grew by 8.3% year-over-year, from $854.5M to $925.3M in fiscal year 2026.

Is Usana Health Sciences Inc profitable?

Yes, Usana Health Sciences Inc (USNA) reported a net income of $10.8M in fiscal year 2026, with a net profit margin of 1.2%.

What is Usana Health Sciences Inc's EBITDA?

Usana Health Sciences Inc (USNA) had EBITDA of $70.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Usana Health Sciences Inc's gross margin?

Usana Health Sciences Inc (USNA) had a gross margin of 78.3% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Usana Health Sciences Inc's operating margin?

Usana Health Sciences Inc (USNA) had an operating margin of 4.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Usana Health Sciences Inc's net profit margin?

Usana Health Sciences Inc (USNA) had a net profit margin of 1.2% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Usana Health Sciences Inc's return on equity (ROE)?

Usana Health Sciences Inc (USNA) has a return on equity of 2.0% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Usana Health Sciences Inc's free cash flow?

Usana Health Sciences Inc (USNA) generated $8.5M in free cash flow during fiscal year 2026. This represents a -83.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Usana Health Sciences Inc's operating cash flow?

Usana Health Sciences Inc (USNA) generated $22.3M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Usana Health Sciences Inc's total assets?

Usana Health Sciences Inc (USNA) had $739.0M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Usana Health Sciences Inc's capital expenditures?

Usana Health Sciences Inc (USNA) invested $13.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Usana Health Sciences Inc spend on research and development?

Usana Health Sciences Inc (USNA) invested $10.7M in research and development during fiscal year 2026.

Does Usana Health Sciences Inc buy back shares?

Yes, Usana Health Sciences Inc (USNA) spent $27.5M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Usana Health Sciences Inc have outstanding?

Usana Health Sciences Inc (USNA) had 18M shares outstanding as of fiscal year 2026.

What is Usana Health Sciences Inc's current ratio?

Usana Health Sciences Inc (USNA) had a current ratio of 2.51 as of fiscal year 2026, which is generally considered healthy.

What is Usana Health Sciences Inc's debt-to-equity ratio?

Usana Health Sciences Inc (USNA) had a debt-to-equity ratio of 0.27 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Usana Health Sciences Inc's return on assets (ROA)?

Usana Health Sciences Inc (USNA) had a return on assets of 1.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Usana Health Sciences Inc's Altman Z-Score?

Usana Health Sciences Inc (USNA) has an Altman Z-Score of 4.06, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Usana Health Sciences Inc's Piotroski F-Score?

Usana Health Sciences Inc (USNA) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Usana Health Sciences Inc's earnings high quality?

Usana Health Sciences Inc (USNA) has an earnings quality ratio of 2.08x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Usana Health Sciences Inc cover its interest payments?

Usana Health Sciences Inc (USNA) has an interest coverage ratio of 44.5x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Usana Health Sciences Inc?

Usana Health Sciences Inc (USNA) scores 45 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.